Guido Felizzia

Guido Felizzia

Auto-generated profile, based on publicly available information

Guido Felizzia

52Hematology-Oncology Unit, Paediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2026 in Blood Advances
Verified
Journal Article
Open access
JDJean Donadieu
Jean Donadieu
DEDmitry Evseev
Dmitry Evseev
FPFrancesco Pegoraro
Francesco Pegoraro
ESElena Sieni
Elena Sieni
OSOlga Slater
Olga Slater
MMMilen Minkov
Milen Minkov
We evaluated long-term outcomes of 288 children with refractory-Langerhans cell histiocytosis (R-LCH) from 26 countries, who were prescribed off-label MAPK inhibitors (MAPKis) according to clinical indications. MAPKi indications included 148 R-risk-organ–positive (R-RO+), 67 R-risk-organ–negative (R-RO–), 13 lung destruction (lung), 9 sclerosing cholangitis (SC), 49 neurodegeneration (ND), and 2 diabetes insipidus (DI) cases. Median ages at diagnosis and MAPKi onset were 1.3 and 2.3 years, respectively, with median follow-up of 3.7 years (1166 person-years). Agents mostly prescribed as monotherapies were 184 prescriptions of vemurafenib, 115 of dabrafenib, 3 of encorafenib, 42 of cobimetinib, 45 of trametinib, and/or 1 prescription of binimetinib; followed 51 times by various chemotherapies or hematopoietic stem-cell transplantation, or 28 times by combined anti-BRAF–anti-MEK. Short-term responses (<8 weeks) ranged from 98% (R-RO+ and R-RO–), to 30% (lung) to none (ND, DI, and SC); although long-term lung and ND responses could be observed. Skin rash was the most frequent adverse event (∼55%), and 7 others included 1 case of cardiomyopathy and 6 of retinitis. Five developed MAPKi-unrelated tumors and 9 patients died. Five-year survival was 98%. After 113 patients with R-LCH discontinued MAPKi, 69 experienced disease reactivation. None of the various empirical maintenance therapies were able to prevent secondary reactivation. Among the 143 assessable patients without ND-LCH at MAPKi onset, 60 developed ND (45%, 5-year risk). MAPKis appeared to be safe and effective in children with R-RO+/RO–LCH, whereas other indications’ responses were less frequent or occurred later. Further studies are needed to find effective maintenance-therapy approaches, particularly to prevent frequently observed secondary ND.

1 December 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
GVGabriela Villanueva
Gabriela Villanueva
SASandra Alarcón
Sandra Alarcón
DBDiana Bonilla
Diana Bonilla
ACAlejandra Casanovas
Alejandra Casanovas
MCMauricio Chaparro
Mauricio Chaparro
MVMilena Villarroel
Milena Villarroel
PURPOSE: To develop a Latin American expert consensus to support, guide, and accelerate the approval and equitable access to anti-GD2 immunotherapy for patients with high-risk neuroblastoma (HR-NB) in the region. Survival rates for HR-NB have improved with the incorporation of anti-GD2 immunotherapy; however, despite the approval of two commercial anti-GD2 therapies in two countries, access remains limited in Latin America. METHODS AND RESULTS: A systematic review was conducted of studies published from January 2004 through February 2025. Of 401 studies identified, 29 met inclusion criteria and served as the basis for four expert consensus statements on the use of anti-GD2 immunotherapy: (1) Newly diagnosed HR-NB maintenance therapy: Anti-GD2 immunotherapy as maintenance treatment for all newly diagnosed HR-NB patients is strongly recommended to maximize event-free survival and reduce the need for morbid and costly salvage therapies. (2) Relapsed/refractory NB: Early integration (at first relapse) of anti-GD2 immunotherapy in salvage treatment is recommended. (3) Role of high-dose chemotherapy with autologous stem-cell transplant (ASCT): Some argue that anti-GD2 immunotherapy obviates the need for ASCT. However, until results of randomized trials omitting ASCT are available, the panel recommends continued use of ASCT where it is available. (4) Newly diagnosed HR-NB: incorporation of anti-GD2 during induction/consolidation: Pilot studies using early anti-GD2 immunotherapy plus chemotherapy showed promising results but is not recommended until confirmed by larger studies with well-defined control arms. CONCLUSION: This consensus highlights the urgent need to expand access to anti-GD2 therapy in Latin America as maintenance therapy for newly diagnosed patients with HR-NB and patients with relapsed or refractory neuroblastoma. Collaboration between health policymakers, the pharmaceutical industry, the Global Platform for Access to Childhood Cancer Medicines, and the pediatric oncology community is essential to address this challenge.

14 May 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
GFGuido Felizzia
Guido Felizzia
Valeria SegatoriValeria Segatori
Valeria Segatori
LGLaura Galluzzo
Laura Galluzzo
DADaniel F. Alonso
Daniel F. Alonso
NPNicolás Pinto
Nicolás Pinto
WCWalter Cacciavillano
Walter Cacciavillano

28 June 2025 in Principles and Practice of Clinical Research Journal
Verified
Journal Article
Open access
PDF file
NKNantawan Koonalinthip
Nantawan Koonalinthip
RTRogerio Diniz Takahashi
Rogerio Diniz Takahashi
SSSão Paulo Centro de Diagnósticos Brasil - Alliança Saúde
São Paulo Centro de Diagnósticos Brasil - Alliança Saúde
TSTatiana Soares
Tatiana Soares
JLJose Gabriel Lara-Amador
Jose Gabriel Lara-Amador
GFGuido Felizzia
Guido Felizzia
Background: Exposure to environmental pollution, particularly air pollutants, and its relationship with childhood central nervous system (CNS) tumors is a growing public health concern. Understanding these associations is crucial for the implementation of protective measures for children and the development of strategic public policies. Objective: This systematic review examines the association between air pollution exposure and the risk of CNS tumors in the pediatric population aged 0-19 years. Methods: Following PRISMA guidelines, we used PubMed, SCOPUS, EMBASE, Google Scholar, and CENTRAL baselines up to May 2024. We included only observational studies focusing on children exposed to air pollutants, excluding tobacco-related exposures. Data on study design, population characteristics, exposure assessment, and types of CNS tumors were extracted and analyzed. Results: We included 25 studies (case-control and cohort) conducted across North America, Europe, Australia, and Asia. The studies assessed pollutants such as benzene, nitrogen dioxide (NO2), particulate matter (PM2.5), and polycyclic aromatic hydrocarbons (PAHs). Some studies reported positive associations between specific pollutants and increased CNS tumor risk, while others found no significant links. Variability in exposure assessment methods contributed to inconsistent findings. Conclusion: The evidence linking air pollution to childhood CNS tumors remains inconclusive. Further research, with standardized exposure assessments and consideration of critical exposure windows, is needed to clarify these associations and inform public health policies to reduce environmental risks to children.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
STSofía Trobo
Sofía Trobo
NGNatalia Perez Garrido
Natalia Perez Garrido
PRPablo Ramirez
Pablo Ramirez
FTFiorella Tesan
Fiorella Tesan
EVElisa Vaiani
Elisa Vaiani
RMRoxana Marino
Roxana Marino
Background/Objective: DICER1 ‐related tumor predisposition is a rare hereditary tumor predisposition disorder characterized by autosomal dominant inheritance, reduced penetrance, and variable expressivity. This study is aimed at describing the clinical and molecular spectrum of DICER1 ‐related tumor predisposition in an Argentine pediatric cohort. Design and Methods: Seventeen unrelated patients with DICER1 ‐related tumor predisposition and 54 relatives were evaluated at “Prof. Dr. J. P. Garrahan” Pediatric Hospital (Buenos Aires, Argentina) between 2014 and 2024. Germline and somatic DICER1 variants were analyzed using Sanger or next‐generation sequencing. Functional assays were performed for selected intronic variants. Three samples of poorly differentiated thyroid carcinoma were also included. Results: Sixteen distinct germline variants were identified in the 17 index cases, including 12 novel alterations (75%). One quarter of the variants were de novo. Thyroid involvement, particularly multinodular goiter and papillary thyroid carcinoma, was the most common presentation and frequently coexisted with ovarian Sertoli–Leydig cell tumors or embryonal rhabdomyosarcoma. Two novel intronic variants were confirmed to affect splicing by RT‐PCR. Somatic “hotspot” mutations in exons 24–25 (RNase IIIb domain) were detected in most tumors, consistent with the two‐hit model. The identification of asymptomatic carriers enabled early surveillance and preventive interventions. Conclusions: This study expands the molecular spectrum of germline DICER1 variants, reinforces the predominance of thyroid involvement, and highlights the value of molecular testing for diagnosis, genetic counseling, and early intervention. Ethical considerations regarding surveillance and management of asymptomatic carriers remain an important area in need of future guidance.